Find the lowest price from 7,500+ FDA-registered pharmacies. Save up to 90%.
⭐ 4.7/5 Customer Rating
🏅 FDA-Registered Pharmacies
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
Blocks histamine H1 receptors directly at target tissues — a second line of action that manages symptoms even when some mediator release occurs.
Tirzepatide combined with NAD+ pairs the most potent weight-loss injectable available with a fundamental coenzyme in cellular energy production and repair. This combination targets both aggressive appetite suppression and the cellular metabolic demands that accompany significant weight loss.
Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Tirzepatide activates both GIP and GLP-1 receptors, producing the most significant appetite suppression and metabolic improvement of any currently available injectable. NAD+ is a coenzyme essential for mitochondrial ATP synthesis, DNA repair via PARP enzymes, and sirtuin activation. Together, they address both caloric intake reduction and the heightened cellular energy demands during rapid weight loss.
No commercially available product combines tirzepatide with NAD+. NAD+ must be delivered by injection because oral NAD+ is rapidly degraded in the GI tract. Compounding allows prescribers to deliver both agents in a single subcutaneous injection, combining the most effective weight-loss peptide with direct cellular energy support.
Compounded tirzepatide with NAD+ represents one of the most advanced GLP-1 combination formulations available through compounding pharmacies. Tirzepatide's dual GIP/GLP-1 mechanism produces weight loss of up to 22.5% of body weight — significantly more than any single-receptor agonist. NAD+ addresses the cellular metabolic demands that accompany this level of physiological change.
NAD+ (nicotinamide adenine dinucleotide) is required for over 500 enzymatic reactions in the body, including mitochondrial energy production, DNA repair, and sirtuin-mediated stress responses. During rapid weight loss, cellular metabolic demands increase while nutrient intake decreases — a combination that can deplete NAD+ pools and contribute to fatigue, brain fog, and reduced cellular resilience.
This combination is most commonly prescribed in longevity-focused and functional medicine practices where optimizing cellular health alongside aggressive weight management is a priority.
Tirzepatide — Dual GIP/GLP-1 Receptor Activation
Tirzepatide activates both GIP receptors (enhancing insulin sensitivity in adipose tissue, promoting fat mobilization) and GLP-1 receptors (suppressing appetite, slowing gastric emptying, stimulating glucose-dependent insulin secretion). The dual mechanism produces metabolic effects that exceed either pathway alone, resulting in the greatest weight loss observed in clinical trials of injectable therapies.
NAD+ — Cellular Energy and Longevity
NAD+ is the primary electron carrier in the mitochondrial electron transport chain, powering ATP synthesis. It is consumed by sirtuins (SIRT1–SIRT7) to regulate inflammation, metabolic adaptation, and cellular stress responses. PARP enzymes consume NAD+ during DNA repair. During rapid metabolic change from tirzepatide therapy, maintaining adequate NAD+ levels supports cellular resilience and energy production.
Prescribed for patients with a documented clinical need for compounded tirzepatide who also benefit from cellular energy optimization:
BIND THIS TO: Mechanism Text CMS field (Rich Text). Then delete this paragraph and add a Rich Text element instead.
Anti-aging and longevity protocols, chronic fatigue, neurodegenerative disease support, addiction recovery, post-COVID fatigue
⚠️ Dosing should be determined by your prescriber. The information below is general guidance only.
Typical tirzepatide + NAD+ dosing:
Weeks 1–4: Tirzepatide 2.5mg + NAD+ 25–50mg weekly
Weeks 5–8: Tirzepatide 5mg + NAD+ 25–50mg weekly
Weeks 9–12: Tirzepatide 7.5mg + NAD+ 50–100mg weekly
Weeks 13–16: Tirzepatide 10mg + NAD+ 50–100mg weekly
Weeks 17+: Tirzepatide 12.5–15mg + NAD+ 50–100mg weekly
NAD+ dosing varies by prescriber protocol. Dosing is individualized.
Follow standard tirzepatide titration (2.5mg start, increase every 4 weeks). NAD+ may cause transient flushing at higher doses — starting low and increasing gradually minimizes this. The flushing is not related to tirzepatide and resolves within minutes. Patients who cannot tolerate tirzepatide dose increases should hold at the current tolerated dose.
Subcutaneous Injection — The standard form. Tirzepatide and NAD+ are combined in a single vial for weekly injection. Subcutaneous delivery is better tolerated than IV NAD+ infusions and allows at-home self-administration.
From tirzepatide:
From NAD+:
GI side effects are primarily from tirzepatide. NAD+ flushing is separate and resolves quickly.
Compounded tirzepatide + NAD+ is a 503A patient-specific preparation. Neither the combination nor NAD+ for injection is individually FDA-approved. The FDA resolved the tirzepatide shortage in late 2024; compounding remains legal for patients with documented clinical needs. Patients should verify pharmacy licensure, sterility testing, and potency verification.
Each additive addresses different clinical needs. B12 supports general nutrient repletion and nerve health. L-carnitine enhances fat oxidation. NAD+ supports fundamental cellular energy production, DNA repair, and longevity pathways (sirtuins). Prescribers choose based on the patient's primary goals — NAD+ is most commonly selected for patients prioritizing cellular health and anti-aging alongside weight management.
Generally yes. NAD+ is a more costly active ingredient than B12 or L-carnitine, and tirzepatide is more expensive than semaglutide. Pricing typically ranges from $279 to $599 per month. Compounding Finder helps you compare options to find the best value.
No. Neither the combination nor compounded NAD+ injections are individually FDA-approved. Tirzepatide is the same active ingredient in FDA-approved Mounjaro and Zepbound. NAD+ is a naturally occurring coenzyme. The combination is prepared by licensed compounding pharmacies under a valid prescription.
Some patients experience transient flushing, warmth, or mild nausea shortly after injection. These effects typically resolve within minutes and are less pronounced with subcutaneous delivery compared to IV infusion. Starting with a lower NAD+ dose can minimize these effects.
Yes. Compounded tirzepatide + NAD+ requires a valid prescription from a licensed healthcare provider.
1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
2. Rajman L, et al. Therapeutic Potential of NAD-Boosting Molecules. Cell Metab. 2018;27(3):529-547.
3. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
4. Verdin E. NAD+ in Aging, Metabolism, and Neurodegeneration. Science. 2015;350(6265):1208-1213.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
